Express . . . Reducing the risk of disease progression in patients with triple-negative breast cancer was reduced by 59%, and innovative antibody conjugate drugs reached stage 3 clinical endpoint.

▎ immunomedics announced today that troldvy (sacituzumab govitecan hziy), an antibody coupled drug developed by the company, has reached the primary end point of progression free survival (PFS) in a confirmatory phase 3 ascent clinical trial for patients with metastatic triple negative breast cancer (mtnbc), reducing the risk of disease progression or death by 59%.trodelvy has previously obtained FDA accelerated approval based on objective remission rate and duration data in a single arm phase 2 clinical trial.the company plans to submit an application for the license of supplemental biological products (SBLA) to FDA for full approval of trodelvy based on the three phase clinical data.triple negative breast cancer (TNBC) is an invasive breast cancer, accounting for 20% of all breast cancers.it is more common in young and premenopausal women.TNBC cells do not express estrogen, progesterone receptors, or human epidermal growth factor receptor 2 (HER2), which means that drugs targeting these receptors are usually ineffective in TNBC.there is no approved standard treatment for mtnbc patients who have received previous treatment.trodelvy is an antibody coupled drug (ADC) targeting Trop-2 antigen. Trop-2 is a cell surface protein expressed in many solid cancers.by binding with Trop-2, troldvy delivers an anticancer drug SN-38, killing cancer cells.it is worth mentioning that Everest, a biomedical company invested and established by c-bridge capital, on April 29, last year Medicines) announced that it has entered into an exclusive license agreement with immunomedics to obtain the development, registration and commercialization rights of this innovative antibody coupled drug in Greater China, South Korea and some Southeast Asian countries and regions.the total amount of this cooperation is up to 835 million US dollars.recently, the drug evaluation center (CDE) of the State Drug Administration of China announced that the antibody coupled drug submitted by Yunding Xinyao company has been approved for a clinical application in China, and the indication is "metastatic triple negative breast cancer who has received at least two lines of previous treatment".photo source: CDE official website screenshot related reading: 835 million US dollars introduction! Everest's heavyweight anticancer ADC drug approved in China! In the ascent study, more than 500 patients with metastatic triple negative breast cancer were randomly treated with trodelvy or a doctor's choice of chemotherapy. These patients received at least two previous treatments for metastatic diseases.the results showed that compared with chemotherapy, troldvy reduced the risk of disease progression or death by 59% (HR = 0.41, 95% CI, 0.32-0.52).the median PFS was 5.6 months (95% CI, 4.3-6.3) and 1.7 months (95% CI, 1.5-2.6) for patients treated with trodelvy and 1.7 months (95% CI, 1.5-2.6) (P & lt; 0.0001).trodelvy also reached the key secondary end points of the study, including overall survival and objective response rate. The complete results will be published at the upcoming medical meeting."the results of ascent, a global phase 3 clinical trial, confirm our preliminary observation that sacituzumab govitecan may change the standard treatment of mtnbc. "said Dr. Aditya Bardia, a professor of medicine at Harvard Medical School, who led the clinical trial. References: [1] immunologic announcements positive results from phase 3 ascent study of treadlevy ™ In previously treated patients with metastatic triple negative breast cancer (mtnbc). if you need guidance on treatment plan, please go to a regular hospital.